Trial Profile
A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors SillaJen Biotherapeutics
- 24 Oct 2023 Results from phase 2 study assessing antitumor activity and safety of intravenous (IV) or intratumoral(IT) PV in combination with cemiplimab (REGN2810, anti-PD-1 inhibitor) in patients with metastatic or unresectable renal cell carcinoma presented at the 48th European Society for Medical Oncology Congress
- 26 Oct 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
- 03 Aug 2022 Status changed from recruiting to active, no longer recruiting.